Evidence map›Paper›PMID 41136407›Full record

ArticleNature communications2025

Oligomeric HIV-1 integrase structures reveal functional plasticity for intasome assembly and RNA binding.

Tao Jing, Zelin Shan, Tung Dinh, Avik Biswas, Sooin Jang, Juliet Greenwood, Min Li, Zeyuan Zhang, Gennavieve Gray, Hye Jeong Shin and 11 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Mechanistic insights into lenacapavir-induced off-pathway HIV-1 capsid assembly.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Tao Jing *The Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-1936-4392
Zelin Shan *The Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-4983-3575
Tung DinhDivision of Infectious Diseases, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA.ORCID http://orcid.org/0000-0002-5141-3281
Avik BiswasThe Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-3519-3944
Sooin JangDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Juliet GreenwoodDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Min LiNational Institutes of Health, National Institute of Diabetes and Digestive Diseases, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-7119-2148
Zeyuan ZhangThe Salk Institute for Biological Studies, La Jolla, CA, USA.
Gennavieve GrayThe Salk Institute for Biological Studies, La Jolla, CA, USA.
Hye Jeong ShinThe Salk Institute for Biological Studies, La Jolla, CA, USA.
Bo ZhouThe Salk Institute for Biological Studies, La Jolla, CA, USA.
Dario PassosThe Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-1333-9102
Timothy S StrutzenbergThe Salk Institute for Biological Studies, La Jolla, CA, USA.
Sriram AiyerThe Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-6436-0521
Leonardo AndradeThe Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-0004-5677
Yuxuan ZhangThe Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID http://orcid.org/0009-0009-7213-3877
Zhen LiDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Robert CraigieNational Institutes of Health, National Institute of Diabetes and Digestive Diseases, Bethesda, MD, USA.
Alan N EngelmanDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9709-2591
Mamuka KvaratskheliaDivision of Infectious Diseases, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, CO, USA.ORCID http://orcid.org/0000-0003-3800-0033
Dmitry LyumkisThe Salk Institute for Biological Studies, La Jolla, CA, USA. dlyumkis@salk.edu.ORCID http://orcid.org/0000-0002-8124-7472

Funding

Viral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Alan Saghatelian · 1985 to 2026
$82.8M
Structural Biology CoreU54AI170855 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI Alan N. Engelman · 2022 to 2026
$36.7M
Project 3. IntegrationU54AI170791 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ANGELA M. GRONENBORN · 2022 to 2026
$30.6M
Biochemical Mechanism of HIV DNA IntegrationR37AI039394 · NIAID · DANA-FARBER CANCER INST · PI Alan N. Engelman · 2010 to 2026
$10.2M
Resource for Biocomputing Visualization and InformaticsP41GM103311 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2012 to 2017
$8.2M
Ultra-potent HIV capsid inhibitorsR01AI157802 · NIAID · UNIVERSITY OF COLORADO DENVER · PI JAMES R FUCHS, Mamuka Kvaratskhelia · 2020 to 2026
$7.1M
Roles of HIV-1 capsid-binding FG-motif containing cellular cofactors in infectionR01AI162665 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Mamuka Kvaratskhelia, Gregory B Melikian · 2022 to 2026
$3.9M
BIOCHEMICAL MECHANISM OF HIV DNA INTEGRATIONR01AI039394 · NIAID · DANA-FARBER CANCER INSTITUTE · PI ENGELMAN, ALAN N. · 1996 to 2009
$3.8M
Structural basis for activity of and resistance to HIV integrase inhibitorsR01AI136680 · NIAID · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI LYUMKIS, DMITRY · 2017 to 2021
$3.5M
Structural basis for activity of and resistance to HIV integrase inhibitorsU01AI136680 · NIAID · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI LYUMKIS, DMITRY · 2022 to 2025
$3.4M
Novel mechanism of integrase (IN) resistance to Dolutegravir through epistatic interactions between IN and the nucleocapsid and polypurine tract regions of HIV-1R01AI146017 · NIAID · EMORY UNIVERSITY · PI HACHIYA, ATSUKO, LYUMKIS, DMITRY · 2019 to 2023
$2.6M
Role of HIV-1 integrase in virion morphogenesis and its targeting by allosteric integrase inhibitorsR01AI184419 · NIAID · UNIVERSITY OF COLORADO DENVER · PI JAMES R FUCHS, Sebla B. Kutluay · 2024 to 2026
$2.4M
NCI NIH HHS P30 CA014195NIAID NIH HHS R01 AI039394NIAID NIH HHS R01 AI136680NIAID NIH HHS R01 AI146017NIAID NIH HHS R01 AI157802NIAID NIH HHS R01 AI162665NIAID NIH HHS R01 AI184419NIAID NIH HHS R37 AI039394NIAID NIH HHS U01 AI136680NIAID NIH HHS U54 AI170791NIAID NIH HHS U54 AI170855NIGMS NIH HHS F32 GM148049NIGMS NIH HHS P41 GM103311NIGMS NIH HHS R01 GM151305NIH HHS S10 OD032467U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI039394U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI136680U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI146017U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI170791U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI170855U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI184419U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) GM148049
6 · The paper itself

Abstract

Integrase (IN) performs dual essential roles during HIV-1 replication. During ingress, IN functions within an oligomeric "intasome" assembly to catalyze viral DNA integration into host chromatin. During late stages of infection, tetrameric IN binds viral RNA and orchestrates the condensation of ribonucleoprotein complexes into the capsid core. The molecular architectures of HIV-1 IN assemblies that mediate these distinct events remain unknown. Furthermore, the IN tetramer is an important antiviral target for investigational allosteric IN inhibitors. Here, we determined cryo-EM structures of wildtype HIV-1 IN tetramers and intasome hexadecamers. Our structures unveil a remarkable plasticity that leverages IN C-terminal domains and abutting linkers to assemble functionally distinct oligomeric forms. Alteration of a newly recognized conserved interface revealed that both IN functions track with tetramerization in vitro and during HIV-1 infection. Collectively, our findings reveal how IN plasticity orchestrates its diverse molecular functions and suggest a working model for IN-viral RNA binding. Moreover, our structure of the IN tetramer provides atomic blueprints for the rational development of improved allosteric inhibitors.

Indexed as

HIV-1HIV IntegraseRNA, ViralCryoelectron MicroscopyHumansModels, MolecularProtein BindingProtein MultimerizationVirus IntegrationHIV Integrasep31 integrase protein, Human immunodeficiency virus 1RNA, Viral

Identifiers

PMID41136407
PMCPMC12552619

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.